CR10097A - Compuestos dímeros agonistas de los receptores de los fgf (fgfr). - Google Patents

Compuestos dímeros agonistas de los receptores de los fgf (fgfr).

Info

Publication number
CR10097A
CR10097A CR10097A CR10097A CR10097A CR 10097 A CR10097 A CR 10097A CR 10097 A CR10097 A CR 10097A CR 10097 A CR10097 A CR 10097A CR 10097 A CR10097 A CR 10097A
Authority
CR
Costa Rica
Prior art keywords
fgfr
compounds
diary
fgf
agonist
Prior art date
Application number
CR10097A
Other languages
English (en)
Inventor
Francoise Bono
Nathalie Guillo
Jean-Pierre Maffrand
Pierre Fons
Jacob-Alsboek Olsen
Gilles Anne-Archard
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CR10097A publication Critical patent/CR10097A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos nuevos heterocíclicos inductores de la dimerización de los receptores de los factores de crecimiento de los fibroblastos (FGFR), según la formula I, su proceso de preparación y sus aplicaciones terapéuticas.
CR10097A 2006-01-13 2008-06-20 Compuestos dímeros agonistas de los receptores de los fgf (fgfr). CR10097A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600317A FR2896247B1 (fr) 2006-01-13 2006-01-13 Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CR10097A true CR10097A (es) 2008-10-29

Family

ID=36808846

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10097A CR10097A (es) 2006-01-13 2008-06-20 Compuestos dímeros agonistas de los receptores de los fgf (fgfr).

Country Status (36)

Country Link
US (1) US9120819B2 (es)
EP (1) EP2018165B1 (es)
JP (1) JP5286088B2 (es)
KR (1) KR101378220B1 (es)
CN (1) CN101384258B (es)
AR (1) AR059001A1 (es)
AT (1) ATE505188T1 (es)
AU (1) AU2007204252B2 (es)
BR (1) BRPI0707132A2 (es)
CA (1) CA2633057C (es)
CR (1) CR10097A (es)
CY (1) CY1111688T1 (es)
DE (1) DE602007013889D1 (es)
DK (1) DK2018165T3 (es)
EA (1) EA015046B1 (es)
EC (1) ECSP088592A (es)
ES (1) ES2364857T3 (es)
FR (1) FR2896247B1 (es)
HN (1) HN2008001067A (es)
HR (1) HRP20110514T1 (es)
IL (1) IL192403A (es)
JO (1) JO2659B1 (es)
MA (1) MA30214B1 (es)
MX (1) MX2008009010A (es)
NO (1) NO20083406L (es)
NZ (1) NZ569631A (es)
PE (1) PE20071115A1 (es)
PL (1) PL2018165T3 (es)
PT (1) PT2018165E (es)
RS (1) RS51872B (es)
SI (1) SI2018165T1 (es)
TN (1) TNSN08250A1 (es)
TW (1) TWI386408B (es)
UA (1) UA95469C2 (es)
WO (1) WO2007080325A1 (es)
ZA (1) ZA200806547B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
US8901341B2 (en) 2011-02-11 2014-12-02 Bezwada Biomedical, Llc Amino acid derivatives and absorbable polymers therefrom
WO2012167261A2 (en) 2011-06-03 2012-12-06 Yale University Compositions and methods for treating and preventing neointimal stenosis
FR2982261B1 (fr) * 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
CA2904794C (en) * 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
EP2994130A4 (en) * 2013-05-06 2017-02-22 Bush, Andrew B. Fgf modulation of in vivo antibody production and humoral immunity
EP3741397B1 (en) 2015-12-11 2025-05-21 Research Institute at Nationwide Children's Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
WO2025045826A1 (en) 2023-08-25 2025-03-06 The Cultivated B. Gmbh Compounds for activation of fgfr1 signaling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
MX2008009010A (es) 2008-09-25
AU2007204252A1 (en) 2007-07-19
EA200870167A1 (ru) 2009-12-30
PL2018165T3 (pl) 2011-09-30
WO2007080325A8 (fr) 2008-10-23
ECSP088592A (es) 2008-08-29
EA015046B1 (ru) 2011-04-29
PE20071115A1 (es) 2007-12-14
TNSN08250A1 (en) 2009-10-30
SI2018165T1 (sl) 2011-08-31
IL192403A (en) 2012-10-31
NO20083406L (no) 2008-10-13
CA2633057C (fr) 2014-10-21
TWI386408B (zh) 2013-02-21
JP2009523160A (ja) 2009-06-18
CN101384258A (zh) 2009-03-11
NZ569631A (en) 2011-04-29
ZA200806547B (en) 2009-12-30
JP5286088B2 (ja) 2013-09-11
ATE505188T1 (de) 2011-04-15
KR101378220B1 (ko) 2014-03-27
PT2018165E (pt) 2011-07-14
RS51872B (sr) 2012-02-29
MA30214B1 (fr) 2009-02-02
KR20090006060A (ko) 2009-01-14
EP2018165B1 (fr) 2011-04-13
US20090069368A1 (en) 2009-03-12
WO2007080325A1 (fr) 2007-07-19
AU2007204252B2 (en) 2012-05-24
DE602007013889D1 (de) 2011-05-26
ES2364857T3 (es) 2011-09-15
HN2008001067A (es) 2011-01-24
BRPI0707132A2 (pt) 2011-04-19
CY1111688T1 (el) 2015-10-07
IL192403A0 (en) 2008-12-29
HRP20110514T1 (hr) 2011-08-31
AR059001A1 (es) 2008-03-05
HK1130009A1 (en) 2009-12-18
CN101384258B (zh) 2013-06-26
TW200738708A (en) 2007-10-16
DK2018165T3 (da) 2011-08-01
FR2896247A1 (fr) 2007-07-20
JO2659B1 (en) 2012-06-17
UA95469C2 (ru) 2011-08-10
FR2896247B1 (fr) 2008-02-29
CA2633057A1 (fr) 2007-07-19
US9120819B2 (en) 2015-09-01
EP2018165A1 (fr) 2009-01-28

Similar Documents

Publication Publication Date Title
CR10097A (es) Compuestos dímeros agonistas de los receptores de los fgf (fgfr).
UY34561A (es) Compuestos dímeros agonistas de los receptores de los fgf (fgfr), su procedimiento de preparación y su aplicación en terapéutica.
UY34560A (es) Compuestos dímeros agonistas de los receptores de los fgf (fgfr),su proceso de preparación y su aplicación en terapéutica.
CR20120348A (es) Nuevos compuestos tricíclicos
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
CR20120421A (es) Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa
EA201000113A1 (ru) Пиразольные соединения
PA8793301A1 (es) Imidazoles bicíclicos fusionados
UY34300A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
SV2009003300A (es) Nuevos herbicidas
ECSP10010366A (es) Derivados de pirimidina 5-fluoro como fungicidas
UY33801A (es) COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
CY1110010T1 (el) Πυριδιναμινοσουλφονυλ υποκατεστημενα βενζαμιδια ως αναστολεις κυτοχρωματος ρ450 3α4 (cyp3a4)
SV2010003514A (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.
MA32957B1 (fr) Derives de quinazolinone utiles comme antagonistes vanilloides
CR20120032A (es) Derivados de 5-fluoro-2-oxopirimidinona-1(2h)-carboxamida substituida-n1
ECSP12011651A (es) Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato
ECSP12011653A (es) Derivados de n1-acil-5-fluoropirimidinona
CR10286A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
CR20130541A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como receptores vegf de inhibidores de cinasa

Legal Events

Date Code Title Description
MA Abandonment or withdrawal (discontinuation of right)